Detalhe da pesquisa
1.
The farnesoid X receptor regulates adipocyte differentiation and function by promoting peroxisome proliferator-activated receptor-gamma and interfering with the Wnt/beta-catenin pathways.
J Biol Chem
; 285(47): 36759-67, 2010 Nov 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-20851881
2.
Obesity resistant mechanisms in the Lean polygenic mouse model as indicated by liver transcriptome and expression of selected genes in skeletal muscle.
BMC Genomics
; 12: 96, 2011 Feb 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-21291556
3.
Human apolipoprotein A-II determines plasma triglycerides by regulating lipoprotein lipase activity and high-density lipoprotein proteome.
Arterioscler Thromb Vasc Biol
; 30(2): 232-8, 2010 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-19910634
4.
Atheroprotective effect of human apolipoprotein A5 in a mouse model of mixed dyslipidemia.
Circ Res
; 103(5): 450-3, 2008 Aug 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-18658049
5.
Tissue-specific roles of ABCA1 influence susceptibility to atherosclerosis.
Arterioscler Thromb Vasc Biol
; 29(4): 548-54, 2009 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-19201688
6.
Rexinoid bexarotene modulates triglyceride but not cholesterol metabolism via gene-specific permissivity of the RXR/LXR heterodimer in the liver.
Arterioscler Thromb Vasc Biol
; 29(10): 1488-95, 2009 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-19592467
7.
Despite antiatherogenic metabolic characteristics, SCD1-deficient mice have increased inflammation and atherosclerosis.
Arterioscler Thromb Vasc Biol
; 29(3): 341-7, 2009 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-19095997
8.
Combination therapy of statins and fibrates in the management of cardiovascular risk.
Curr Opin Lipidol
; 20(6): 505-11, 2009 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-19829109
9.
Intestinal ABCA1 directly contributes to HDL biogenesis in vivo.
J Clin Invest
; 116(4): 1052-62, 2006 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-16543947
10.
Efficacy of peroxisome proliferator-activated receptor agonists in diabetes and coronary artery disease.
Curr Atheroscler Rep
; 11(4): 281-8, 2009 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-19500491
11.
Reduced plasma high-density lipoprotein cholesterol in hyperthyroid mice coincides with decreased hepatic adenosine 5'-triphosphate-binding cassette transporter 1 expression.
Endocrinology
; 149(7): 3708-12, 2008 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-18388200
12.
Both hepatic and extrahepatic ABCA1 have discrete and essential functions in the maintenance of plasma high-density lipoprotein cholesterol levels in vivo.
Circulation
; 114(12): 1301-9, 2006 Sep 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-16940190
13.
Peroxisome proliferator-activated receptor alpha improves pancreatic adaptation to insulin resistance in obese mice and reduces lipotoxicity in human islets.
Diabetes
; 55(6): 1605-13, 2006 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-16731822
14.
Increased ABCA1 activity protects against atherosclerosis.
J Clin Invest
; 110(1): 35-42, 2002 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-12093886
15.
Genetically-engineered animals as research models for atherosclerosis: their use for the characterization of PPAR agonists in the treatment of cardiometabolic disorders.
Front Biosci
; 12: 4132-56, 2007 May 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-17485363
16.
The RXR agonist bexarotene improves cholesterol homeostasis and inhibits atherosclerosis progression in a mouse model of mixed dyslipidemia.
Arterioscler Thromb Vasc Biol
; 26(12): 2731-7, 2006 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-17008586
17.
Cholesterol 7alpha-hydroxylase deficiency in mice on an APOE*3-Leiden background increases hepatic ABCA1 mRNA expression and HDL-cholesterol.
Arterioscler Thromb Vasc Biol
; 26(12): 2724-30, 2006 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-17008588
18.
PPARalpha and PPARgamma dual agonists for the treatment of type 2 diabetes and the metabolic syndrome.
Curr Opin Pharmacol
; 6(6): 606-14, 2006 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-16973418
19.
Paradoxical exacerbation of combined hyperlipidemia in human apolipoprotein A-II transgenic mice treated with fenofibrate.
Biochim Biophys Acta
; 1737(2-3): 130-7, 2005 Dec 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-16226489
20.
PPARalpha, but not PPARgamma, activators decrease macrophage-laden atherosclerotic lesions in a nondiabetic mouse model of mixed dyslipidemia.
Arterioscler Thromb Vasc Biol
; 25(9): 1897-902, 2005 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-15994444